Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Taladegib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Taladegib overview

Taladegib (LY-2940680) is under development for the treatment of idiopathic pulmonary fibrosis (IPF) and advanced solid tumors harboring PTCH1 loss of function mutations. The drug candidate targets smoothened (SMO) receptor. The drug candidate is administered through oral route. It was also under development for advanced cancers including epithelial ovarian, fallopian tube or primary peritoneal cancer and adenocarcinoma of the esophagus or gastroesophageal junction, small cell lung cancer, recurrent or refractory rhabdomyosarcoma, refractory medulloblastoma and as a topical formulation for superficial and nodular basal cell carcinoma.

Endeavor BioMedicines overview

Endeavor BioMedicines (Endeavor) is a clinical-stage company developing a best-in-class Hedgehog inhibitor for idiopathic pulmonary fibrosis. It designs and develops hedgehog inhibitors for the treatment of idiopathic pulmonary fibrosis (IPF). The company is investigating ENV-101, a small-molecule inhibitor to treat basal cell carcinoma and acute myelogenous leukemia by targeting and activating the hedgehog signaling pathway during embryonic development. It also investigates ENV-501, an antibody-drug conjugate.

For a complete picture of Taladegib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.